Economic evaluation of human papillomavirus vaccination in developed countries

Public Health Genomics

Volumn 12, Issue 5-6, 2009, Pages 343-351

  Brisson, Marc ^a,b   Van De Velde, Nicolas ^a,b   Boily, Marie Claude ^b,c  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cost effectiveness; Economic evaluation; Human papillomavirus; Mathematical model; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CONSENSUS; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; ECONOMIC EVALUATION; HUMAN; INFECTION PREVENTION; MEDICAL LITERATURE; PEER REVIEW; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTION; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 69249106516     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000214924     Document Type: Article

References (41)

1. Paavonen J, Jenkins D, Bosch FX, et al: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-2170.
2. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943.
3. FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
4. Rambout L, Hopkins L, Hutton B, Fergusson D: Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007; 177: 469-479.
5. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ: Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008; 100: 308-320.
6. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G: A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007; 4: 165-175.
7. Boot HJ, Wallenburg I, de Melker HE, Mangen MJ, Gerritsen AA, van der Maas NA, Berkhof J, Meijer CJ, Kimman TG: Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine 2007; 25: 6245-6256.
8. Brisson M, Van de Velde N, De Wals P, Boily MC: Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ 2007; 177: 464-468.
9. French KM, Barnabas RV, Lehtinen M, Kontula O, Pukkala E, Dillner J, Garnett GP: Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 2007; 96: 514-518.
10. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ: Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166: 137-150.
11. Brisson M, Van de Velde N, De Wals P, Boily MC: The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25: 5399-5408.
12. Van de Velde N, Brisson M, Boily MC: Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007; 165: 762-775.
13. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V: Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 2008; 24: 10-19.
14. Elbasha EH, Dasbach EJ, Insinga RP: Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41.
15. Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M: Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007; 96: 143-150.
16. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP: Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3:e138.
17. Taira AV, Neukermans CP, Sanders GD: Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-1923.
18. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-615.
19. Sanders GD, Taira AV: Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9: 37-48.
20. Kulasingam SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781-789.
21. Günther OP, Ogilvie G, Naus M, Young E, Patrick DM, Dobson S, Duval B, Noël PA, Marra F, Miller D, Brunham RC, Pourbohloul B: Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity? J Infect Dis 2008; 197: 1653-1661.
22. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE: Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008; 14: 244-251.
23. Jit M, Choi YH, Edmunds WJ: Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337:a769.
24. Kim JJ, Goldie SJ: Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359: 821-832.
25. Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER: Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008; 6: 4.
26. Dasbach EJ, Insinga RP, Elbasha EH: The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008; 115: 947-956.
27. Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S: Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008; 24: 1473-1483.
28. Llamazares M, Smith RJ: Evaluating human papillomavirus vaccination programs in Canada: should provincial healthcare pay for voluntary adult vaccination? BMC Public Health 2008; 8: 114.
29. Kim JJ, Brisson M, Edmunds J, Goldie SJ: Modeling cervical cancer prevention in developed countries. Vaccine 2008;26(suppl 10):K76-K86.
30. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds): Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1996.
31. Beutels P: Economic Evaluation of Vaccination Programmes in Humans: A Methodological Exploration with Applications to Hepatitis B, Varicella-Zoster, Measles, Pertussis, Hepatitis A and Pneumococcal Vaccination. Antwerp, University of Antwerp, 2001.
32. Drummond MF, O'Brien B, Stoddart GL, Torrance GW: Methods for the Evaluation of Health Care Programmes. New York, Oxford University Press, 1997.
33. Boily MC, Abu-Raddad L, Desai K, Masse B, Self S, Anderson R: Measuring the publichealth impact of candidate HIV vaccines as part of the licensing process. Lancet Infect Dis 2008; 8: 200-207.
34. Parkin DM, Bray F: Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24(suppl 3):S11-S25.
35. Lacey CJ, Lowndes CM, Shah KV: Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24(suppl 3):S35-S41.
36. Koopman JS: Modeling infection transmission- the pursuit of complexities that matter. Epidemiology 2002; 13: 622-624.
37. Brisson M, Edmunds WJ: Economic evaluation of vaccination programmes: the impact of herd-immunity. Med Decis Making 2003; 23: 76-82.
38. Brisson M, Edmunds WJ: Impact of Model, Methodological and Parameter Uncertainty in the Economic Evaluation of Vaccination Programs. Med Decis Making 2006; 26: 434-446.
39. Beutels P, Scuffham PA, MacIntyre CR: Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 2008; 8: 727-733.
40. Weinstein MC, O'Brien B, Hornberger J, et al: Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003; 6: 9-17.
41. Marra F, Gunther O, Ogilvie G, Marra CA, Pourbohloul B, Ehlen T, Miller D, Naus M, Patrick DM, Brunham RC: A dynamic model to determine cost effectiveness of HPV vaccine in girls and boys in Canada. ISSTDR, Seattle, July 2007.